FDA
-
-
-
-
-
-
-
Galmed reports 500% bioavailability boost for oral aramchol formulation
-
-
-
-
-
-
-
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
-
-
-
-
-
-
-
Galmed CEO outlines drug development plans in shareholder letter
-
-
-
-
-
-
-
Galmed plans to invest up to $10 million in digital assets
-
-
-
-
-
-
-
Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers
-
-
-
-
-
-
-
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
-
-
-
-
-
-
-
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
-
323,939 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

